Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Bioxcel Therapeutics (BTAI) Stock Price & Analysis
1,235 Followers
BTAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.91 - $29.56
Previous Close$2.59
Volume319.97K
Average Volume (3M)1.55M
Market Cap
$87.11M
Enterprise Value$122.92M
Total Cash (Recent Filing)$65.22M
Total Debt (Recent Filing)$101.04M
Price to Earnings (P/E)-0.4
Beta1.41
Next Earnings
May 06, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.16
Shares Outstanding30,576,671
10 Day Avg. Volume401,187
30 Day Avg. Volume1,550,351
Standard Deviation0.35
R-Squared0.00364
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.49
Price to Sales (P/S)217.94
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue89.07
Enterprise Value/Gross Profit1.02K
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$6.30Price Target Upside143.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bioxcel Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBioXcel Therapeutics announced details of the planned TRANQUILITY In-Care Phase 3 trial, indicating progress in their clinical development for the treatment of Alzheimer's disease agitation.
Financial HealthBioXcel Therapeutics' recent $25 million equity raise, expected to extend the company's cash runway into the fourth quarter of 2024, demonstrates strengthened financial stability.
Regulatory CollaborationThe TRANQUILITY In-Care trial's design, based on feedback from the FDA, showcases a collaborative effort with the agency to evaluate BXCL501's efficacy and safety.
Bears Say
Clinical TrialsInitiation of key clinical trials for schizophrenia/bipolar disease and metastatic pancreatic cancer has been delayed.
Financial HealthThe company's cash reserves decreased significantly.
Revenue ForecastThe commercial Igalmi program has been deprioritized, leading to a reduction in the revenue forecast for 2024.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.91 and its highest was $29.56 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Currently, no data Available
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Mar 12, 2024. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.917 by $0.157.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -$0.7.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 33,631,280 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.917. Following the earnings report the stock price went down -4.483%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at N/A.
---
Bioxcel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.30 (143.24% Upside)
$6.30 (143.24% Upside)
Blogger Sentiment
Bearish
BTAI Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.93%
12-Months-Change
Fundamentals
Return on Equity
-1766.94%
Trailing 12-Months
Asset Growth
-64.20%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q4 2024
0:00 / 0:00
---
BTAI Stock 12 Months Forecast
Average Price Target
$6.30
▲(143.24% Upside)
Technical Analysis
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/36 ratings generated profit
1 Year Average Return
+53.00%
reiterated a buy rating last month
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +53.00% per trade.
---